Sun Pharma response to import ban inadequate - FDA

Tue May 20, 2014 10:22pm IST

A logo of Sun Pharmaceutical Industries Ltd at its research and development center in Mumbai April 7, 2014.  REUTERS/Danish Siddiqui/Files

A logo of Sun Pharmaceutical Industries Ltd at its research and development center in Mumbai April 7, 2014.

Credit: Reuters/Danish Siddiqui/Files

Related Topics

Stocks

   

REUTERS - Generic drugmaker Sun Pharmaceutical Industries Ltd's (SUN.NS) response to an import ban on one of its plants lacked "sufficient corrective actions," the U.S. Food and Drug Administration said in a warning letter published on Tuesday.

The FDA banned imports from Sun Pharma's Karkhadi plant in Gujarat in March, but the reason for the ban was not clear at that time.

In the warning letter dated May 7 and posted on the FDA website on Tuesday, the regulator said Sun Pharma failed to ensure laboratory records had complete data and that manufacturing staff had inadequate training and experience.

"Your firm frequently performs 'unofficial testing' of samples, disregards the results, and reports results from additional tests," the FDA said in the letter addressed to Sun Pharma CEO Subramanian Kalyanasundaram. (link.reuters.com/pyx49v)

A Sun Pharma spokesman told Reuters on Tuesday that the warning letter shows that the U.S. FDA does not agree with the company's response.

The Karkhadi plant, which makes the antibiotic cephalosporin, is one of Sun Pharma's 25 manufacturing plants.

Sun Pharma, which is planning to buy its struggling rival Ranbaxy Laboratories Ltd (RANB.NS) for $3.2 billion, had said in March that the import ban would have negligible financial impact.

The FDA has unleashed a wave of restrictions, warnings and bans on Indian generic drug firms over the past one year, citing serious manufacturing and quality control problems.

(Reporting by Esha Dey in Bangalore and Zeba Siddiqui in Mumbai; Editing by Sriraj Kalluvila)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Earnings Season

REUTERS SHOWCASE

Monsoon Revives

Monsoon Revives

Monsoon revival keeps rain above average   Full Article 

Tackling Food Prices

Tackling Food Prices

India to free up extra 10 million tonne wheat in open market  Full Article 

Facebook Results

Facebook Results

Facebook beats Wall Street targets, stock hits record high  Full Article 

Struggling Economies

Struggling Economies

Asian economies to struggle on weak export demand - Reuters poll  Full Article 

Mining Roadblock

Mining Roadblock

Coal India's plans for 20 mines hit by land, environment delays  Full Article 

Power Jolt

Power Jolt

UAE's TAQA pulls out of India power plant deal with Jaiprakash  Full Article 

Factory Sector

Factory Sector

China July HSBC flash PMI at 18-month high of 52.0   Full Article 

Currency Reserves

Currency Reserves

Sri Lankan, Indian central banks agree scope for government debt buys.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage